Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of August 19, 2026, ABT trades at $112.63 with a market cap of $190.98B and a P/E ratio of 36.52. ABT moved +2.09% today. Year to date, ABT is -10.06%; over the trailing twelve months it is -13.50%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $121.79. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ABT insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $112.63 |
| Market Cap | $190.98B |
| P/E Ratio | 36.52 |
| EPS | $3.10 |
| Dividend Yield | 0.63% |
| 52-Week High | $141.23 |
| 52-Week Low | $81.97 |
| Volume | 5.30M |
| Avg Volume | 0 |
| Revenue (TTM) | $46.59B |
| Net Income | $5.42B |
| Gross Margin | 56.61% |
16 analysts cover ABT: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $121.79.